Nina A. Makretskaya, O. Bezlepkina, A. Kolodkina, A. Kiyaev, E. Vasilyev, V. Petrov, O. Chikulaeva, O. Malievsky, I. Dedov, A. Tyulpakov
{"title":"Study of molecular basis of thyroid dysgenesis","authors":"Nina A. Makretskaya, O. Bezlepkina, A. Kolodkina, A. Kiyaev, E. Vasilyev, V. Petrov, O. Chikulaeva, O. Malievsky, I. Dedov, A. Tyulpakov","doi":"10.14341/KET9556","DOIUrl":null,"url":null,"abstract":"Congenital hypothyroidism is a heterogeneous group of diseases, which is manifested by loss of function of the thyroid gland that affects infants from birth. 80–85% of cases are due to different types of thyroid dysgenesis. 5 genes have been described that are involved in the pathogenesis of thyroid dysgenesis: TSHR, PAX8, FOXE1, NKX2-1, NKX2-5. \nAims. To evaluate the prevalence of mutations in the genes TSHR, PAX8, FOXE1, NKX2-1, NKX2-5 among patients with severe congenital hypothyroidism. \nMaterials and methods. 161 patients (64 boys, 97 girls) with congenital hypothyroidism (TSH levels at neonatal screening or retesting greater than 90 mU/l) were included in the study. 138 subjects had different variants of thyroid dysgenesis, and 23 patients had normal volume of the gland. A next generation sequencing was used for molecular-genetic analysis. Sequencing was performed using PGM semiconductor sequencer (Ion Torrent, Life Technologies, USA) and a panel “Hypothyroidism” (Custom DNA Panel). Assessment of the pathogenicity of sequence variants were carried out according to the latest international guidelines (ACMG, 2015). \nResults. 13 patients had variants in thyroid dysgenesis genes (8,1%, 13/161): TSHR, n = 6; NKX2-1, n = 3; NKX2-5, n = 1; PAX8, n = 3; FOXE1, n = 0. \nConclusions. Mutations in thyroid dysgenesis genes are a rare pathology. The majority of variants among our patients were identified in TSHR.","PeriodicalId":10284,"journal":{"name":"Clinical and experimental thyroidology","volume":"30 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental thyroidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/KET9556","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Congenital hypothyroidism is a heterogeneous group of diseases, which is manifested by loss of function of the thyroid gland that affects infants from birth. 80–85% of cases are due to different types of thyroid dysgenesis. 5 genes have been described that are involved in the pathogenesis of thyroid dysgenesis: TSHR, PAX8, FOXE1, NKX2-1, NKX2-5.
Aims. To evaluate the prevalence of mutations in the genes TSHR, PAX8, FOXE1, NKX2-1, NKX2-5 among patients with severe congenital hypothyroidism.
Materials and methods. 161 patients (64 boys, 97 girls) with congenital hypothyroidism (TSH levels at neonatal screening or retesting greater than 90 mU/l) were included in the study. 138 subjects had different variants of thyroid dysgenesis, and 23 patients had normal volume of the gland. A next generation sequencing was used for molecular-genetic analysis. Sequencing was performed using PGM semiconductor sequencer (Ion Torrent, Life Technologies, USA) and a panel “Hypothyroidism” (Custom DNA Panel). Assessment of the pathogenicity of sequence variants were carried out according to the latest international guidelines (ACMG, 2015).
Results. 13 patients had variants in thyroid dysgenesis genes (8,1%, 13/161): TSHR, n = 6; NKX2-1, n = 3; NKX2-5, n = 1; PAX8, n = 3; FOXE1, n = 0.
Conclusions. Mutations in thyroid dysgenesis genes are a rare pathology. The majority of variants among our patients were identified in TSHR.
先天性甲状腺功能减退症是一种异质性疾病,其表现为甲状腺功能丧失,从出生开始影响婴儿。80-85%的病例是由于不同类型的甲状腺发育不良。目前已知有5个基因参与甲状腺发育不良的发病机制:TSHR、PAX8、FOXE1、NKX2-1、NKX2-5。目标评估重度先天性甲状腺功能减退症患者TSHR、PAX8、FOXE1、NKX2-1、NKX2-5基因突变的患病率。材料和方法。161例先天性甲状腺功能减退(新生儿筛查或复检TSH水平大于90 mU/l)患者(男64例,女97例)纳入研究。138例患者有不同类型的甲状腺发育不良,23例患者甲状腺体积正常。采用新一代测序技术进行分子遗传分析。测序使用PGM半导体测序仪(Ion Torrent, Life Technologies, USA)和“甲状腺功能减退”面板(Custom DNA panel)。根据最新的国际指南(ACMG, 2015年)对序列变异的致病性进行了评估。结果:13例患者存在甲状腺发育不良基因变异(8.1%,13/161):TSHR, n = 6;NKX2-1, n = 3;NKX2-5, n = 1;PAX8, n = 3;FOXE1, n = 0。结论。甲状腺发育不良基因的突变是一种罕见的病理。在我们的患者中,大多数变异是在TSHR中发现的。